Unveiling MGI's Customer Experience Center in Berlin: Empowering Precision Medicine

MGI, a pioneering company in the life science industry, is delighted to announce the launch of its new Customer Experience Center (CEC) in Berlin, Germany. This cutting-edge facility, located at ALACRiS Theranostics GmbH (ALACRiS)'s premises, is a major milestone in MGI's mission to empower precision medicine through advanced technology platforms and innovative clinical solutions in oncology.

A Partnership for Precision Medicine

MGI has formed a strategic partnership with ALACRiS Theranostics, a renowned precision network in oncology, to bring MGI's cutting-edge automation and sequencing platforms to a national level in Germany. This collaboration is designed to drive the advancement of precision medicine by providing MGI's state-of-the-art products for various cancer indications, including bladder, colorectal, and stomach, within a growing network of local clinical centers. By leveraging ALACRiS's expertise and MGI's groundbreaking technologies, this partnership is set to revolutionize cancer diagnostics and treatment, ultimately improving patient outcomes.

Leaders in Genomic Research and Precision Medicine

ALACRiS Theranostics, founded in 2008 by Professor Dr. Hans Lehrach, a renowned pioneer in genomic research, is at the forefront of translating innovative scientific discoveries into tangible benefits for patients. With a strong focus on precision medicine, ALACRiS strives to enable novel approaches in cancer therapy through the integration of cutting-edge technologies and clinical expertise. The establishment of the Customer Experience Center in Berlin further reinforces ALACRiS's commitment to advancing precision medicine and fostering collaboration within the scientific community.

The newly launched Customer Experience Center will serve as a pivotal hub for ALACRiS to leverage MGI's DNBSEQ-G400 sequencers and MGISP-960 automation system. Equipped with MGI's state-of-the-art technologies, ALACRiS will collaborate closely with local German and Benelux hospitals, including renowned institutions like Helios Universitätsklinikum Wuppertal, to provide personalized and precise oncology services. Moreover, the center will serve as an innovation-driven facility, allowing MGI to conduct product testing, demonstrations, training sessions, experiments, and welcome customer visits.

Advancing Molecular Tumor Analysis and Precision Medicine

MGI's cutting-edge technology plays a pivotal role in supporting ALACRiS's comprehensive molecular tumor analysis (CMTA) approach, which encompasses the analysis of genetic alterations in tumors to guide personalized treatment strategies. The collaboration between MGI and ALACRiS will provide benchmark data and an end-to-end workflow for both clinical and research applications. By developing, distributing, and harmonizing wet lab protocols, the partners aim to ensure the highest quality and precision of processes, ultimately facilitating an individualized approach to cancer therapy. This joint effort has the potential to revolutionize cancer diagnostics, accelerate research advancements, and drive the adoption of precision medicine on a global scale.

Driving Innovation and Collaboration

"MGI's automation and sequencing platforms perfectly align with ALACRiS's molecular oncology and precision medicine services," said Dr. Marie-Laure Yaspo, Founder & Chief Scientific Officer at ALACRiS Theranostics. The establishment of the Customer Experience Center solidifies ALACRiS's position as a regional hub, providing exceptional customer experiences and fostering innovation in research and translational projects. This collaboration between MGI and ALACRiS demonstrates their shared commitment to transforming the field of precision medicine and revolutionizing healthcare outcomes.

Dr. Yong Hou, General Manager of MGI Europe and Africa, further commented, "Through the application of ALACRiS's clinical solutions based on MGI's cutting-edge technology and the establishment of an open network of leading stakeholders, MGI will support ALACRiS in implementing and executing their comprehensive molecular tumor analysis approach. This collaboration will not only expand from Germany to partner labs internationally but also grant broader access to MGI's state-of-the-art tools and technologies, fostering scientific progress and transforming healthcare globally."

Note: Availability of DNBSEQ-G400 sequencers and other products may vary by region. Please refer to the respective company websites for specific details.